Figure 3.

Adverse effect of B-HAIC and sorafenib on advanced HCC. (A,B) Changes in the Child-Pugh scores and eGFR before and after the treatments. The Child-Pugh score continuously increased during the medication of sorafenib. (C) Approximately half of the patients had to discontinue the use of sorafenib because of the reasons other than disease progression. (D) The B-HAIC group patients exhibited a higher rate of additional chemotherapy than the sorafenib group. B-HAIC, bi-monthly hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma; eGFR, estimated glomerular filtration rate; NS, non-significant.